Table 4.
Relative vaccine effectiveness of the fourth dose against all-cause mortality in individuals aged 80 years and older by number of days after the fourth dose, and according to sex, age, and time passed since vaccination.
| Fourth-dose group |
Third-dose group |
Relative vaccine effectiveness (95% CI) |
||||
|---|---|---|---|---|---|---|
| Deaths | Deaths/100,000 person-days | Deaths | Deaths/100,000 person-days | Adjusted for age and baseline date | Fully adjusted* | |
| 7-60 days, total cohort (N = 365,249) | 2040 | 17·4 | 2659 | 45·3 | 64 (62-66) | 71 (69-72) |
| Men (N = 151,823) | 887 | 17·9 | 1195 | 50·5 | 67 (65-70) | 71 (69-74) |
| Women (N = 213,426) | 1153 | 17·0 | 1464 | 41·8 | 62 (59-65) | 70 (68-72) |
| Age >85 years (N = 186,451) | 1520 | 25·2 | 1957 | 66·4 | 64 (62-67) | 71 (69-73) |
| Age ≤85 years (N = 178,798) | 520 | 9·1 | 702 | 24·0 | 65 (61-69) | 70 (67-74) |
| >4 months since vaccination in the third-dose group (N = 134,831) | 859 | 18·5 | 1353 | 80·6 | 78 (77-80) | 79 (77-81) |
| ≤4 months since vaccination in the third-dose group (N = 230,418) | 1181 | 16·6 | 1,306 | 31·2 | 50 (46-54) | 61 (58-64) |
| >4 months since vaccination in the fourth-dose group (N = 308,446) | 1815 | 18·3 | 2298 | 46·3 | 63 (61-66) | 71 (69-72) |
| 61-143 days, total remaining cohort (N = 243,880) | 757 | 4·8 | 297 | 7·8 | 46 (38-53) | 54 (48-60) |
CI=confidence interval.
⁎
Adjusted for age, baseline date, sex, born in Sweden, and residence in long-term care facility.